Literature DB >> 31499119

Noninvasive imaging in cancer immunotherapy: The way to precision medicine.

Yang Du1, Yafei Qi2, Zhengyu Jin3, Jie Tian4.   

Abstract

Molecular medicine requires a more precise treatment directed at molecular aberrations detected in tumors on an individual patient level. Immunotherapies empower the body's own immune system to confront tumor cells; however, their efficacy is often affected by tumor heterogeneity. Numerous noninvasive imaging techniques are available to monitor changes in tumor function reflecting therapeutic response, including immunotherapy, and to realize personalized response evaluation. For immunotherapy, strategies for using noninvasive imaging as a prognostic biomarker to identify patients who could benefit from targeted immunotherapy and predict early responders/nonresponders may ultimately lead to improved clinical management, individualized therapy regimens, and better prediction of patient outcomes. Herein, we summarize the recent progress in noninvasive imaging of immunotherapeutic targets such as immune cells, immune checkpoint inhibitors, immune vaccines, and T-cell therapy with chimeric antigen receptor, and review the clinical application of noninvasive imaging in immunotherapy. Finally, we describe the application of multimodal/multispectral imaging and radiomics, which may offer future direction for precision imaging in immunotherapy. With further progress of noninvasive imaging, guiding cancer immunotherapy into the era of precision medicine would be a promising option.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Immune checkpoint inhibitor; Immunotherapy; Molecular imaging; Precision medicine

Mesh:

Substances:

Year:  2019        PMID: 31499119     DOI: 10.1016/j.canlet.2019.08.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study.

Authors:  Jian-Xian Lin; Jun-Peng Lin; Yong Weng; Chen-Bin Lv; Jian-Hua Chen; Chuan-Yin Zhan; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Wen-Xing Zhou; Xiao-Jing Zhang; Chao-Hui Zheng; Li-Sheng Cai; Yu-Bin Ma; Chang-Ming Huang
Journal:  Ann Surg Oncol       Date:  2022-03-16       Impact factor: 5.344

2.  Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers.

Authors:  Ying Zhu; Wang Yao; Bing-Chen Xu; Yi-Yan Lei; Qi-Kun Guo; Li-Zhi Liu; Hao-Jiang Li; Min Xu; Jing Yan; Dan-Dan Chang; Shi-Ting Feng; Zhi-Hua Zhu
Journal:  BMC Cancer       Date:  2021-10-30       Impact factor: 4.430

3.  Glucose-Thymidine Ratio as a Metabolism Index Using 18F-FDG and 18F-FLT PET Uptake as a Potential Imaging Biomarker for Evaluating Immune Checkpoint Inhibitor Therapy.

Authors:  Sera Oh; Hyewon Youn; Jin Chul Paeng; Young-Hwa Kim; Chul-Hee Lee; Hongyoon Choi; Keon Wook Kang; June-Key Chung; Gi Jeong Cheon
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

Review 4.  Medical imaging and nuclear medicine: a Lancet Oncology Commission.

Authors:  Hedvig Hricak; May Abdel-Wahab; Rifat Atun; Miriam Mikhail Lette; Diana Paez; James A Brink; Lluís Donoso-Bach; Guy Frija; Monika Hierath; Ola Holmberg; Pek-Lan Khong; Jason S Lewis; Geraldine McGinty; Wim J G Oyen; Lawrence N Shulman; Zachary J Ward; Andrew M Scott
Journal:  Lancet Oncol       Date:  2021-03-04       Impact factor: 41.316

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.